Medicare's New Coverage Model for Weight-Loss Drugs

Eli Lilly announced that some Medicare beneficiaries may face costs exceeding the anticipated $50 monthly cap for GLP-1 weight-loss drugs under a new federal coverage model. This model, initiated by the Centers for Medicare and Medicaid Services (CMS), aims to expand access to medications like Lilly's Zepbound and Mounjaro, which are used to treat obesity and diabetes. While most Medicare Part D plans are expected to adhere to the $50 out-of-pocket limit, a minority may not fully comply, leading to potential variations in cost-sharing for beneficiaries.

Newsweek

The new coverage model, set to take effect on January 1, 2027, represents a significant shift in how weight-loss drugs are covered under Medicare. Currently, GLP-1 medications can cost patients over $1,000 per month without insurance, although actual costs can vary based on individual insurance plans and discounts. With the expansion of Medicare and Medicaid coverage, beneficiaries may see reduced costs through copays or negotiated rates.

Newsweek

Medical experts indicate that while patients may experience reduced hunger shortly after starting GLP-1 treatments, substantial weight loss typically occurs over a period of three to five months. The effectiveness of these medications can vary based on the specific drug, dosage, and individual patient response.

Newsweek

Eli Lilly emphasized its commitment to helping patients access medications at the lowest possible cost within the Medicare framework. The company noted that the new model is designed to provide standardized coverage terms and net prices, ultimately aiming to lower patient costs while integrating lifestyle and behavioral support.

Newsweek

Despite the potential benefits, there are concerns regarding the variability in cost-sharing across different Medicare Part D plans. Critics argue that the lack of uniformity may create confusion and financial strain for some beneficiaries, undermining the intended accessibility of these essential medications.

Newsweek

While Eli Lilly has stated that most Medicare plans will honor the $50 cap, the exact number of plans that may not comply remains unclear. This discrepancy raises questions about the overall effectiveness of the new coverage model and its impact on patient access to GLP-1 drugs.

Newsweek

As the implementation date approaches, stakeholders, including healthcare providers and patient advocacy groups, will likely monitor the rollout of this new coverage model closely. Further discussions may arise regarding the need for additional regulations to ensure consistent access and affordability for all Medicare beneficiaries.

Newsweek